Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked faithfully but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last few shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely promotional picture in the Uptick Newswire interview that I came away with a bad opinion of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and associated intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) as well as the very first brand new drug application endorsement ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this single treatments and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease types, multiple publications and multiple presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of the interest of mine in this business. Judging by the multiples of thousands of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *